Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edwards Lifesciences Corporation filings document regulatory disclosures for a Delaware medical technology company with common stock listed on the New York Stock Exchange under EW. Recent Form 8-K reports furnish quarterly and annual operating results, including sales commentary tied to transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies.
Proxy and material-event filings cover board elections, executive compensation, shareholder voting results, amendments to the Long-Term Stock Incentive Compensation Program, and senior finance leadership changes. These records also identify the company’s registered common stock structure and formal governance matters submitted to stockholders.
Lippis Daniel J. reported multiple insider transaction types in a Form 4 filing for EW. The filing lists transactions totaling 13,276 shares at a weighted average price of $75.87 per share. Following the reported transactions, holdings were 34,366 shares.
Edwards Lifesciences CEO Bernard J. Zovighian reported several share transactions. On February 12, 2026, he exercised employee stock options covering 25,350 shares of common stock at an exercise price of $59.2567 per share. On the same day, he sold 2,532 shares at a weighted average price of $77.1287 and 19,898 shares at a weighted average price of $76.6133 in open-market transactions.
On February 13, 2026, he reported bona fide gifts of 2,920 shares of common stock at $0.0000 per share in a direct account and 2,920 shares reflected as indirectly held "By Trust." After these transactions, he directly held 80,976 shares, with an additional 11,516.5511 shares held indirectly by a trust and 3,655.5854 shares represented in his 401(k) plan.
Edwards Lifesciences Corp insider Bernard J Zovighian filed a Rule 144 notice to sell 22,430 shares of common stock, with an aggregate market value of $1,719,742.00. The proposed sale is through Charles Schwab & Co., Inc. on the NYSE around 02/12/2026.
The notice states that 580,300,000 shares of common stock were outstanding; this is a baseline figure, not the amount being sold. It also lists prior sales over the past three months of 21,487 and 3,863 Edwards Lifesciences shares, with gross proceeds of $1,831,006.00 and $322,367.00, respectively.
Edwards Lifesciences reported strong growth for the quarter and year ended Dec. 31, 2025, while GAAP earnings were pressured by large one‑time charges. Q4 net sales rose 13.3% to $1.57 billion, led by Transcatheter Aortic Valve Replacement (TAVR) sales of $1.16 billion, up 12.0%, and Transcatheter Mitral and Tricuspid Therapies (TMTT) sales of $156 million, which grew more than 40%.
Q4 diluted EPS from continuing operations was $0.11, while adjusted EPS was $0.58, reflecting exclusions such as $208.6 million of certain litigation expenses and a $99.8 million loss on impairment in the quarter. Full‑year 2025 net sales increased 11.5% to $6.07 billion, with TAVR and TMTT both delivering double‑digit constant‑currency growth.
The company guided to 2026 constant‑currency sales growth of 8–10% and expects TMTT revenue of $740–$780 million, implying 35–45% growth. Edwards also targets 2026 adjusted EPS of $2.90–$3.05 and an adjusted operating margin at the high end of a 28–29% range, supported by a broad structural heart portfolio and multiple product and clinical trial catalysts.
Edwards Lifesciences Corporation reports that the United States District Court for the District of Columbia has granted the U.S. Federal Trade Commission’s motion for an injunction blocking Edwards’ proposed acquisition of JenaValve Technology, Inc. As a direct result of this court action, Edwards states that it will not acquire JenaValve.
The update is presented as an other event and is based on a company press release dated January 9, 2026, which is attached as an exhibit. The filing focuses on the legal outcome affecting this specific transaction and does not provide additional financial figures or broader business updates.
Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, reported an option exercise and related share sale. On 01/09/2026, he exercised an Employee Stock Option for 1,019 shares of common stock at an exercise price of $59.2567 per share and acquired the underlying shares. On the same day, he sold 1,019 shares of common stock at a weighted average price of $85.7037 per share, in multiple trades executed between $85.45 and $85.95.
After these transactions, Lippis directly beneficially owned 22,001.9103 shares of Edwards Lifesciences common stock and 4,076 Employee Stock Options (right to acquire). The filing states that these transactions were carried out under a Rule 10b5-1 trading plan adopted by the reporting person on July 30, 2025.
Edwards Lifesciences reported insider transactions by its CVP, Strategy/Corp Development on 01/06/2026. The executive exercised an employee stock option for 11,340 shares of common stock at an exercise price of $59.2567 per share, then sold 2,632 shares at a weighted average price of $84.6206 and 8,708 shares at a weighted average price of $85.9793.
Following these transactions, the executive directly owned 31,870.2532 shares of common stock and also reported indirect ownership of 38,817.6991 shares through a 401(k) and 135,152 shares held by a trust. After the option exercise, 34,020 employee stock options remained beneficially owned. The filing notes that the transactions were carried out under a Rule 10b5-1 trading plan adopted on February 27, 2025.
Edwards Lifesciences insider Donald E. Bobo Jr. has filed a notice to sell company stock under Rule 144. The planned sale covers 45,360 shares of common stock through broker Charles Schwab & Co., Inc., with an aggregate market value of $3,885,715.00, and relates to an employee stock option exercise using a broker-assisted cashless exercise. The filing notes that 580,300,000 shares of Edwards Lifesciences common stock are outstanding and lists the New York Stock Exchange as the trading venue.
The notice also reports that over the past three months, the same insider sold 11,340 Edwards Lifesciences shares on 12/10/2025 for gross proceeds of $950,582.00 and 11,387 shares on 12/12/2025 for gross proceeds of $953,748.00. By signing the form, the seller represents that he is not aware of any undisclosed material adverse information about the company’s current or prospective operations.
Edwards Lifesciences (EW) reported insider activity by a senior executive. The company’s CVP, Strategy/Corp Development sold 5,486.1175 shares of common stock at $83.79 and 5,900 shares at $83.74 on 12/12/2025. On the same date, 7,100 shares were transferred as a gift at a stated price of $0.00. Following these transactions, the executive directly held 31,870.2532 shares of Edwards Lifesciences common stock, with additional indirect holdings of 38,817.6991 shares through a 401(k) plan and 135,152 shares held by a trust. The report notes that it reflects changes in beneficial ownership only and does not identify all securities of Edwards Lifesciences that the executive may beneficially own.
Edwards Lifesciences reported an insider transaction by a company officer serving as CVP, JAPAC. On 12/12/2025, the officer exercised an employee stock option for 1,019 shares of common stock at an exercise price of $59.2567 per share, then sold the same 1,019 shares in the open market at a weighted average price of $84.0287, with individual sale prices ranging from $83.58 to $84.46.
After these transactions, the officer directly held 22,001.9103 shares of Edwards Lifesciences common stock and 5,095 employee stock options. The filing states that the trades were carried out under a Rule 10b5‑1 trading plan adopted on July 30, 2025, which is a pre-arranged plan intended to allow insiders to sell shares over time according to preset instructions.